Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | MRD: standardization and application

Andrew Rawstron • 22 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Obinutuzumab Rituximab Venetoclax

Andrew Rawstron, PhD, Leeds Teaching Hospitals NHS Trust, Leeds, UK, speaking at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK. Dr Rawston speaks on potential hurdles to overcome when integrating and standardizing MRD in medical practice and clinical trials.

More from Andrew Rawstron

MBL: biology, classification & the possibility of early interception
Andrew Rawstron et al. • 25 Mar 2024
3:48
Predicting suboptimal response through intermediate MRD
Andrew Rawstron • 22 Sep 2019

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals